Charles River Laboratories acquired cGMP contract microbial identification and typing firm Accugenix for $17 million in cash. Charles River says the buyout will strengthen its own endotoxin and microbial detection (EMD) product portfolio by providing clients with microbial detection services for manufacturing in the biopharmaceutical, medical device, and other sectors.

“The acquisition of Accugenix is the first step in our broader strategy to become the premier provider of rapid microbial and endotoxin detection products and services to the biopharmaceutical industry,” states James C. Foster, chairman, president and CEO at Charles River. “Over the next several years we intend to enhance our capabilities through both product extensions and acquisitions.”

Accugenix specializes in the provision of bacterial and fungal identification and strain typing of services to a range of manufacturing industries. The firm says its library databases enable the identification of over 5,000 species.

Previous articleLife and Sino Sign Distribution and Development Pact
Next articleGenmab, Janssen Ink Maybe $1B Antibody Deal